Web20 de jul. de 2024 · Proteolysis-targeting chimeras (PROTACs) are an emerging drug modality that may offer new opportunities to circumvent some of the limitations associated with traditional small-molecule therapeutics. Web1 de set. de 2024 · The α-subunits of the hypoxia-inducible factor (HIF) complex are important targets of PHD proteins. PHD-mediated hydroxylation of HIF-α proteins promotes its interaction with ubiquitin E3 ligase von-Hippel-Lindau (pVHL), which leads to HIF-α poly-ubiquitination and rapid degradation by proteasome under normoxia conditions (19, 20, …
Full article: PROTACs– a game-changing technology
Web1 de dez. de 2024 · The prototype PROTAC_ERRα and PROTAC_RIPK2 efficiently degraded ERRα and RIPK2 in a highly specific manner [57]. However, just like other PROTACs, these small molecular VHL-based PROTACs have no tissue specificity in vivo, as PROTAC_ERRα degrades ERRα protein not only in tumor cell but also in heart and … Web8 de fev. de 2024 · Abstract. Defects in the functions of RNA binding proteins (RBPs) are at the origin of many diseases; however, targeting RBPs with conventional drugs has … green mountain hemp coupon
The PROTACtable genome Nature Reviews Drug Discovery
Web1 de out. de 2024 · A PROTAC could bind to the target protein and E3 ligase, ... (HIF-1α) was taken into consideration to design PROTACs. HIF-1α could be degraded rapidly by … Web19 de dez. de 2024 · Knowing that HIF-2α plays a strong reno-protective role in the progression of chronic kidney disease, and protein von Hippel–Lindau (VHL) is a HIF … green mountain herb company